Immunome (IMNM) Invested Capital: 2023-2025
Historic Invested Capital for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $263.9 million.
- Immunome's Invested Capital rose 22.81% to $263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.9 million, marking a year-over-year increase of 22.81%. This contributed to the annual value of $181.2 million for FY2024, which is 51.12% up from last year.
- As of Q3 2025, Immunome's Invested Capital stood at $263.9 million, which was down 1.99% from $269.3 million recorded in Q2 2025.
- Immunome's 5-year Invested Capital high stood at $307.1 million for Q1 2025, and its period low was $6.1 million during Q3 2023.
- Moreover, its 3-year median value for Invested Capital was $214.9 million (2024), whereas its average is $175.0 million.
- Data for Immunome's Invested Capital shows a peak YoY spiked of 3,436.97% (in 2024) over the last 5 years.
- Immunome's Invested Capital (Quarterly) stood at $119.9 million in 2023, then skyrocketed by 51.12% to $181.2 million in 2024, then increased by 22.81% to $263.9 million in 2025.
- Its Invested Capital was $263.9 million in Q3 2025, compared to $269.3 million in Q2 2025 and $307.1 million in Q1 2025.